Wells Fargo raised the firm’s price target on Bristol Myers (BMY) to $62 from $60 and keeps an Equal Weight rating on the shares. While guidance missed consensus, the firm sees some positives in the company’s print, including growth portfolio expectations appear in line, and notes the company announced another $2B restructuring, which could help in out years.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Cytokinetics initiated with a Buy at Citi
- Bristol Myers Squibb Reports Strong 2024 Financial Growth
- Bristol-Myers Squibb: Positive Earnings Call Highlights
- White House readying order to fire thousands of federal health workers, WSJ says
- Camzyos news has negative readthroughs for Cytokinetics, says BofA